Search results for " breast"

showing 10 items of 610 documents

Skin-nipple-sparing mastectomy: The first approach in primary myxoid chondrosarcoma of the breast

2017

Abstract The primary mammary chondrosarcoma corresponds to less than 0,5% of the mammary malignancies. For the period ranging from 1967 to 2014, only 18 cases were reported in the literature. A 41 year old woman found a hard nodule on her external right superior quadrant/axillary prolongation through breast self-examination. The vacuum-assisted core biopsy (VACB) revealed “high grade extra-skeletal myxoid chondrosarcoma”. A skin-nipple-sparing mastectomy with the insertion of a mammary expander was performed. A protocol of adjuvant radiotherapy was also indicated. Until 2013, the gold standard was the radical mastectomy. By 2014, there were two cases of conservative approach to quadrantecto…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentSkin nippleCase Reportmedicine.diseaseMyxoid chondrosarcomaSurgery03 medical and health sciencesQuadrant (abdomen)Myxoid chondrosarcoma of the breast0302 clinical medicineBreast cancerBreast cancer030220 oncology & carcinogenesisSkin-nipple-sparing mastectomymedicine030211 gastroenterology & hepatologySurgeryChondrosarcomabusinessQuadrantectomyMastectomyRadical mastectomyInternational Journal of Surgery Case Reports
researchProduct

Porcine Model for Gluteal Artery Perforator Flap: Anatomy and Technique

2018

Although flap anatomy is well studied on cadavers and microsurgical techniques are well practiced on rats, still there are few training models for learning the techniques of perforator flap harvesting. The cadaver has no bloodstream, so accuracy of dissection cannot be evaluated and flap viability cannot be verified. Training on humans carries a high risk of flap damage. A living model for perforator flap harvest is needed to learn the technique before starting with its clinical application.

medicine.medical_specialtybusiness.industrymedicine.medical_treatmenteducationlcsh:Surgerylcsh:RD1-811030230 surgeryMicrosurgeryeye diseasesPorcine model gluteal artery perforator flap microsurgery breast reconstruction educational trainingSurgeryGluteal Artery Perforator Flap03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesismedicineSurgeryGluteal ArterybusinessBreast reconstructionSICPRE Abstracts
researchProduct

Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardio…

2021

Abstract Aims In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern. Methods and results In a multicentre study, 146 BC patients (56 ± 11 years) were prospectively enrolled and divided into three groups according to the received treatments: AC/EC-Group (doxorubicin or epirubicin + cyclophosphamide), AC/EC/Tax-Group (AC/EC + taxanes), FEC/Tax-Group (fluorouracil + EC + taxanes). Fifty-six patients of the total cohort also received trastuzumab. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were calculated …

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiologyBreast NeoplasmsAnthracyclineAnthracyclines; Breast cancer; Cardiotoxicity; Myocardial strain030204 cardiovascular system & hematologyAnthracyclines Breast cancer Breast Neoplasms Cardiology Cardiotoxicity Echocardiography Female Humans italy Myocardial strain Pharmaceutical Preparations Stroke Volume Trastuzumab Ventricular Function Left Ventricular Dysfunction LeftVentricular Function LeftVentricular Dysfunction Left03 medical and health sciencesBreast cancer0302 clinical medicineTrastuzumabInternal medicineHumansMedicineAnthracyclinesRadiology Nuclear Medicine and imagingeducationeducation.field_of_studyChemotherapyCardiotoxicityEjection fractionbusiness.industryStroke VolumeGeneral MedicineTrastuzumabMyocardial strainChemotherapy regimenCardiotoxicityItalyPharmaceutical PreparationsEchocardiographyFluorouracil030220 oncology & carcinogenesisCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEpirubicinEuropean Heart Journal - Cardiovascular Imaging
researchProduct

Pancoast's syndrome caused by lymph node metastasis from breast cancer.

2018

Pancoast’s syndrome may be the result of neoplastic, inflammatory or infectious disease. We report an unusual case of Pancoast’s syndrome in a patient with metastatic breast cancer. A 54-year-old woman, affected by metastatic breast cancer, presented for severe shoulder pain, paraesthesia and numbness in the right arm. Despite further multiple lines of systemic chemotherapy, she developed a progressive enlargement of retropectoral, supraclavicular and infraclavicular lymph node metastases, which involved brachial plexus, apex of lung and anterior mediastinum. Physical examination revealed severe weakness of proximal muscles of the right arm. Neuropathic pain was managed with pharmacological…

medicine.medical_specialtypain (palliative care)Settore MED/06 - Oncologia MedicaPhysical examinationBreast Neoplasmspain (neurology)03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerFatal OutcomeShoulder PainmedicineHumansPain ManagementBrachial PlexusInfraclavicular Lymph NodeZiconotideLungUnusual Presentation of More Common Disease/Injurymedicine.diagnostic_testperipheral nerve diseasebusiness.industryPancoast SyndromeGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancermedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisNeuropathic painNeuralgiaSettore MED/26 - NeurologiaFemaleRadiologyLymph NodesbusinessBrachial plexus030217 neurology & neurosurgerymedicine.drugBMJ case reports
researchProduct

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

2015

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by…

medicine.medical_treatmentAPOPTOTIC CALRETICULIN EXPOSUREanti-tumor immunityimmunogenicityPHOTODYNAMIC THERAPY0302 clinical medicinetranslational medicineoncoimmunologyImmunology and AllergyCytotoxic T cellMedicineAnti-tumor immunity; Immunogenicity; Immunotherapy; Molecular medicine; Oncoimmunology; Patient prognosis; Translational medicine; Immunology; Immunology and Allergy0303 health sciencesanti-tumor immunity; immunogenicity; immunotherapy; molecular medicine; oncoimmunology; patient prognosis; translational medicineRIBOSOMAL-PROTEIN DIMERClassificationddc:3. Good health030220 oncology & carcinogenesisImmunogenic cell deathMolecular MedicineimmunotherapyACTIVATING POLYPEPTIDE-IIHIGH HYDROSTATIC-PRESSURElcsh:Immunologic diseases. AllergyANTICANCER IMMUNE-RESPONSESImmunology3122 Cancers610 Medicine & healthpatient prognosis03 medical and health sciencesImmune systemHUMAN TUMOR-CELLSFORMYL PEPTIDE RECEPTORS030304 developmental biologybusiness.industryTranslational medicineBiology and Life SciencesCYTOTOXIC T-LYMPHOCYTESImmunotherapyDendritic cellMolecular medicineNEGATIVE BREAST-CANCERImmunologyCancer cellmolecular dicine3111 Biomedicinebusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Tubular carcinoma of the breast: Outcome and loco-regional recurrence in 307 patients

2005

Abstract Purpose The aim of this study is to describe the University of Florence experience in evaluating clinical, pathologic and treatment factors as they are related to the outcome and loco-regional recurrence in patients with tubular breast carcinoma. Material and methods Three hundred and seven patients (median age 56.4 years, range 26–91 years) with histological verified tubular carcinoma of the breast were consecutively treated at University of Florence from 1976 to 2001. All patients were followed for a median of 8.4 years (range 3 months to 20 years). Thirty-seven women underwent mastectomy and 270 underwent breast conserving surgery. Positive axillary nodes were found in 15% of pa…

medicine.medical_treatmentDiseaseSegmentalMastectomy SegmentalBreast cancerDuctalBreast-conserving surgery80 and overBreastAdjuvantMastectomyAged 80 and overCarcinoma Ductal BreastTubular carcinomaGeneral MedicineMiddle AgedCombined Modality TherapyTreatment OutcomeBreast cancer; Radiotherapy; Tubular carcinoma; Adenocarcinoma; Adult; Aged; Aged 80 and over; Antineoplastic Agents Hormonal; Axilla; Breast Neoplasms; Carcinoma Ductal Breast; Chemotherapy Adjuvant; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy Segmental; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards Models; Radiotherapy Adjuvant; Survival Analysis; Tamoxifen; Treatment Outcome; Oncology; SurgeryLocalOncologyChemotherapy AdjuvantLymphatic MetastasisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic Agents HormonalAntineoplastic AgentsBreast NeoplasmsAdenocarcinomaBreast cancermedicineChemotherapyHumansAgedProportional Hazards ModelsChemotherapyRadiotherapyHormonalbusiness.industryCarcinomamedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTamoxifenNeoplasm RecurrenceAxillaRadiotherapy AdjuvantSurgeryTubular carcinomaNeoplasm Recurrence LocalbusinessTamoxifen
researchProduct

In vitro effects of AGNPs exopolysaccharide from Klebsiella Oxytoca DSM29614 on breast cancer cells

2015

nanoparticles antineoplastic molecules breast cancer proteomicSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a m…

2023

BackgroundIn triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available.MethodsWe carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recrui…

neoadjuvant treatmentCancer ResearchOncologytriple negative breast canceradjuvant capecitabineresidual tumorsresidual tumortreatment discontinuationFrontiers in Oncology
researchProduct

Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single …

2022

Background: Medication-Related Osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction mainly associated to bone modifying agents (BMAs). Breast cancer (BC) is the most frequent cancer worldwide. Its therapy can cause cancer treatment-induced bone loss (CTIBL), commonly treated with BMAs. The aims of this retrospective study are: to describe characteristics of BC patients under BMAs for CTIBL; to record any switch to high-dose BMAs; to assess MRONJ onset and to identify any factors associated with it. Patients: Authors included patients referred for MRONJ prevention to the Unit of Oral Medicine (University Hospital of Palermo). Results: Fourteen female BC patients under low-dose BMAs f…

osteonecrosis of the jawbisphosphonatebreast cancerBPosteonecrosis of the jaw; MRONJ; cancer treatment-induced bone loss; CTIBL; breast cancer; osteoporosis; bone metastases; bisphosphonates; BPs; denosumabcancer treatment-induced bone loosteoporosidenosumabPharmacology (medical)MRONJCTIBLbone metastaseOral; Volume 2; Issue 4; Pages: 274-285
researchProduct

p38 MAPK in cadmium-treated MDA-MB231 breast cancer cells

2008

p38 MAPK cadmium breast cancer cellsSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct